Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9Y3EG)

Drug Name
Guadecitabine Drug Info
Synonyms
UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine
Indication
Disease Entry ICD 11 Status REF
Myelodysplastic syndrome 2A37 Phase 3 [1]
Cross-matching ID
PubChem CID
135564655
CAS Number
CAS 929901-49-5
TTD Drug ID
DM9Y3EG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting DNA [cytosine-5]-methyltransferase 1 (DNMT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CC-486 DMTNQB0 Acute myeloid leukaemia 2A60 Phase 3 [2]
S-110 DMXY34J Acute myeloid leukaemia 2A60 Phase 3 [3]
SGI110 DM1NQDW Acute myeloid leukaemia 2A60 Phase 3 [4]
Palifosfamide DMMIYZ7 Soft tissue sarcoma 2B57 Phase 2 [5]
RX-3117 DME8ARP Bladder cancer 2C94 Phase 2 [6]
Antroquinonol DMRGQVZ Non-small-cell lung cancer 2C25.Y Phase 2 [7]
PMID27376512-Compound-MTC-424 DMGNRZU N. A. N. A. Patented [8]
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [8]
PMID27376512-Compound-MTC-422 DM1MVQD N. A. N. A. Patented [8]
PMID27376512-Compound-MTC-423 DM9RSDX N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA [cytosine-5]-methyltransferase 1 (DNMT1) TT6S2FE DNMT1_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
3 S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
4 Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
5 Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
6 Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
7 Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
8 DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.